INCY $73.86 +0.88 (1.21%)

Incyte Corp

Stock Charts Stock Price Earnings Industry Stocks Company Profile

Incyte Stock Charts

The 5 year and 1 year stock charts are below.

Incyte 5 year stock chart
Incyte 5 year stock chart

50 Day Moving Average

The 50 Day Moving Average is at $67.34 which is 9.68% below the stock price of $73.86.

200 Day Moving Average

The 200 Day Moving Average is at 91.29 which is -19.09% below the stock price of $73.86.

INCY Stock Price

Below are a few key dates for the stock price.

Year To Date


The most recent stock price is $73.86.

The Year To Date (YTD) return is -26.79%.

52 Week Low


The 52 Week Low stock price is $60.23 set on Thu, May 3, 2018 which is 48 days ago.

The current price per share is 22.63% above the 52 week low.

52 Week High

Aug 2017

The 52 Week High stock price is $140.11 set on Thu, Aug 31, 2017 which is 293 days ago.

The current price per share is -47.28% below the 52 week high.

All Time High

Mar 2017

The All Time High stock price is $153.15 set on Wed, Mar 15, 2017 which is 462 days ago.

The current price per share is -51.77% below the all time high.


Below is the EPS, P/E Ratio and Earnings Date.

The EPS is -$0.8 and the P/E Ratio is 0.

Earnings Dates

Stocks can make big percentage moves on the earnings announcement.

Companies announce earnings either before the market open or after the close.


The Earnings Release Date for Incyte Corp was Thu, Feb 15, 2018.

Since this earnings release 125 days ago, the stock price is down by -16.23%.


The most recent Earnings Release Date was on Tue, May 1, 2018, which was 50 days ago.

Since this earnings date, the stock price is up by +19.24%.

Incyte Dividend

Below is important Dividend information.

INCY currently does not pay a dividend.

You may like this list of best dividend stocks of 2018.

Biotech & Pharma Industry

Below are other stocks in the same industry as Incyte.

INCY Company Profile

Learn more about Incyte.

Incyte Corp is a Health Care stock that trades on the NASDAQ and has a market capitalization of $15.47 Billion.

http://www.incyte.comIncyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Spend a few minutes browsing the Incyte Corp, web site at

For more information and analysis of INCY, visit Bloomberg, Google Finance, Nasdaq, Yahoo Finance.